Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
Launched on 06/23/2005, the Invesco Dynamic Biotechnology Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.
Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 14, placing it in bottom 13%.
The fund is sponsored by Invesco. It has amassed assets over $221.38 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.
This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.
Annual operating expenses for this ETF are 0.57%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 0.05%.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Amgen Inc (AMGN) accounts for about 5.33% of total assets, followed by Regeneron Pharmaceuticals Inc (REGN) and Opko Health Inc (OPK).
The top 10 holdings account for about 46.21% of total assets under management.
Performance and Risk
So far this year, PBE has added about 3%, and was up about 14.89% in the last one year (as of 09/21/2020). During this past 52-week period, the fund has traded between $39.70 and $62.86.
The ETF has a beta of 1.23 and standard deviation of 27.83% for the trailing three-year period, making it a high risk choice in the space. With about 32 holdings, it has more concentrated exposure than peers.
Invesco Dynamic Biotechnology Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
SPDR SP Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR SP Biotech ETF has $5.57 billion in assets, iShares Nasdaq Biotechnology ETF has $9.19 billion. XBI has an expense ratio of 0.35% and IBB charges 0.46%.
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Click to get this free report
Invesco Dynamic Biotechnology Genome ETF (PBE): ETF Research Reports
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports
OPKO Health, Inc. (OPK): Free Stock Analysis Report
SPDR SP Biotech ETF (XBI): ETF Research Reports
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.